Malathi Hari
Impact in
- Cell Biology top 5%
- Microtubule and mitosis dynamics
- Oncology top 10%
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
Papers in
-
- Ubiquitin and proteasome pathways 6
- 14-3-3 protein interactions 4
- Protein Degradation and Inhibitors 3
- Glycosylation and Glycoproteins Research 3
- Cell Biology 10
- Microtubule and mitosis dynamics 10
- Co-authors
- Fernando Cabral (4 shared papers)Changqing Zeng (3 shared papers)Hailing Yang (1 shared paper)Lee M. Greenberger (7 shared papers)Frank Loganzo (6 shared papers)Sylvia Musto (6 shared papers)Tami Annable (4 shared papers)Xingzhi Tan (4 shared papers)
- Journals
- Blood (4 papers)Molecular Cancer Therapeutics (2 papers)Clinical Cancer Research (1 paper)Pharmaceutical Research (1 paper)Biochemistry (1 paper)
- Partner nations
- United StatesChina
In The Last Decade
Malathi Hari
16 papers receiving 536 citations
Peers
Comparison fields: 5 of 69
- Cell Biology 261
- Oncology 235
- Biotechnology 49
- Molecular Biology 379
- Cancer Research 51
Countries citing papers authored by Malathi Hari
This map shows the geographic impact of Malathi Hari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malathi Hari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malathi Hari more than expected).
Fields of papers citing papers by Malathi Hari
This network shows the impact of papers produced by Malathi Hari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malathi Hari. The network helps show where Malathi Hari may publish in the future.
Co-authors
The 25 scholars most cited alongside Malathi Hari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 129 | |
| 2 | 2006 | 120 | |
| 3 | HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. | 2003 | 97 |
| 4 | Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. | 2003 | 73 |
| 5 | Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. | 2004 | 25 |
| 6 | 2004 | 24 | |
| 7 | 2005 | 22 | |
| 8 | 2012 | 20 | |
| 9 | 2006 | 18 | |
| 10 | 2013 | 18 | |
| 11 | 2007 | 3 | |
| 12 | 2009 | 2 | |
| 13 | 2008 | 2 | |
| 14 | Hemiasterlin analogs exclusively label α-tubulin at the interdimer region and specifically block subtilisin digestion of α-tubulin | 2004 | 1 |
| 15 | 2009 | 1 | |
| 16 | 2007 | 1 | |
| 17 | 2009 | 1 |
About Malathi Hari
Malathi Hari is a scholar working on Molecular Biology, Cell Biology, Oncology, Hematology and Organic Chemistry, having authored 17 papers that have together received 557 indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (10 papers), Multiple Myeloma Research and Treatments (6 papers), Ubiquitin and proteasome pathways (6 papers), Cancer Treatment and Pharmacology (5 papers), 14-3-3 protein interactions (4 papers), Protein Degradation and Inhibitors (3 papers), Glycosylation and Glycoproteins Research (3 papers) and Cancer-related Molecular Pathways (2 papers). The work is most often cited by research in Cell Biology (261 citations), Oncology (235 citations), Biotechnology (49 citations), Molecular Biology (379 citations) and Cancer Research (51 citations). Malathi Hari has collaborated with scholars based in United States and China. Frequent co-authors include Fernando Cabral, Changqing Zeng, Hailing Yang, Lee M. Greenberger, Frank Loganzo, Sylvia Musto, Tami Annable, Xingzhi Tan, Yaqing Wang and Sudha Veeraraghavan. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Clinical Cancer Research, Pharmaceutical Research and Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.